Anemia and Growth Failure Among HIV-Infected Children in India: a Retrospective Analysis by Shet, Anita et al.
 
Anemia and Growth Failure Among HIV-Infected Children in India:
a Retrospective Analysis
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Shet, Anita, Saurabh Mehta, Nirmala Rajagopalan, Chitra Dinakar,
Elango Ramesh, N. M. Samuel, C. K. Indumathi, Wafaie W.
Fawzi, and Anura V. Kurpad. 2009. Anemia and growth failure
among HIV-infected children in India: a retrospective analysis.
BMC Pediatrics 9:37.
Published Version doi:10.1186/1471-2431-9-37
Accessed February 19, 2015 12:53:27 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4584865
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAABioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Pediatrics
Open Access Research article
Anemia and growth failure among HIV-infected children in India: a 
retrospective analysis
Anita Shet*1, Saurabh Mehta2, Nirmala Rajagopalan3, Chitra Dinakar1, 
Elango Ramesh4, NM Samuel5, CK Indumathi1, Wafaie W Fawzi2 and 
Anura V Kurpad6
Address: 1Department of Pediatrics, St John's National Academy of Health Sciences, Bangalore 560034, India, 2Departments of Nutrition and 
Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA, 3Freedom Foundation, Bangalore, India, 4ART Clinic, Namakkal 
Government Hospital, Namakkal, India, 5Concern for AIDS Research and Education, Namakkal, India and 6Division of Nutrition, St John's 
Research Institute, St. John's National Academy of Health Sciences, Bangalore 560034, India
Email: Anita Shet* - anitashet@gmail.com; Saurabh Mehta - smehta@hsph.harvard.edu; Nirmala Rajagopalan - nirmalaskill@gmail.com; 
Chitra Dinakar - chitra_dini@yahoo.com; Elango Ramesh - drrameshart@yahoo.com; NM Samuel - nms_mds@yahoo.com; 
CK Indumathi - ckindumathi@gmail.com; Wafaie W Fawzi - MINA@hsph.harvard.edu; Anura V Kurpad - a.kurpad@iphcr.res.in
* Corresponding author    
Abstract
Background: Anemia and poor nutrition have been previously described as independent risk factors for death
among HIV-infected children. We sought to describe nutritional status, anemia burden and HIV disease correlates
among infected children in India.
Methods: We analyzed retrospective data from 248 HIV-infected children aged 1–12 years attending three
outpatient clinics in South India (2004–2006). Standard WHO definitions were used for anemia, HIV staging and
growth parameters. Statistical analysis included chi square, t tests, univariate and multivariate logistic regression
analyses.
Results: The overall prevalence of anemia (defined as hemoglobin < 11 gm/dL) was 66%, and 8% had severe
anemia (Hb < 7 gm/dL). The proportion of underweight and stunted children in the population was 55% and 46%
respectively. Independent risk factors of anemia by multivariate analysis included the pre-school age group (age
younger than 6 years) (OR: 2.87; 95% CI: 1.45, 5.70; p < 0.01), rural residence (OR: 12.04; 95% CI: 5.64, 26.00; p
< 0.01), advanced HIV disease stage (OR: 6.95; 95% CI: 3.06, 15.79; p < 0.01) and presence of stunting (Height-
for-age Z Score < -2) (OR: 3.24; 95% CI: 1.65, 6.35; p < 0.01). Use of iron/multivitamin supplementation was
protective against risk of anemia (OR: 0.44; 95% CI: 0.22, 0.90; p = 0.03). Pulmonary tuberculosis was an
independent risk factor in multivariate analysis (OR: 3.36; 95% CI: 1.43, 7.89; p < 0.01) when correlated variables
such as HIV disease stage and severe immunodeficiency, and nutritional supplement use were not included. Use
of antiretroviral therapy (ART) was associated with a reduced risk of anemia (OR: 0.29; 95% CI: 0.16, 0.53; p <
0.01). No significant association was found between anemia and gender, cotrimoxazole, or ART type (zidovudine
versus stavudine).
Conclusion: The high prevalence and strong interrelationship of anemia and poor nutrition among HIV-infected
children in India, particularly those living in rural areas underscores the need for incorporating targeted nutritional
interventions during national scale up of care, support and treatment among HIV-infected children.
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Background
Globally, the HIV epidemic remains a serious challenge,
and continues to take its toll particularly on vulnerable
populations such as children. Although revised 2007
UNAIDS epidemiological analyses indicate that the cur-
rent Indian national seroprevalence is 0.36%, ongoing
perinatal transmission substantially impacts the incidence
of paediatric HIV, adding to the large pool of HIV-infected
children in India [1]. In 2005, the National AIDS Control
Organization has dramatically increased access to antiret-
roviral therapy for children, and several thousands of chil-
dren have been successfully initiated on specific anti-HIV
therapy. However, background co-morbidities compound
the problem in affected populations in India. Two such
major co-morbidities include anemia and poor nutrition,
whose detrimental effects are magnified in the context of
HIV infection.
Studies have unequivocally demonstrated that anemia is
associated with decreased survival and increased disease
progression in adults with HIV infection [2-4]. Independ-
ent of other factors, anemia is also associated with a
diminished quality of life [5]. In children with HIV infec-
tion, the high prevalence of anemia is well known[6].
Given that the negative impact of anemia is magnified on
account of its close relation to overall nutrition and
growth, there is limited data from Asian countries where
HIV infection, malnutrition and nutritional deficiencies
co-exist. Understanding nutritional co-morbidities will be
beneficial in planning appropriate intervention strategies
to reduce the overall burden of pediatric HIV in India. In
this report, we describe nutritional status, HIV disease
stage, and correlates of anemia among HIV-infected chil-
dren in South India.
Methods
A retrospective cross-sectional, multicenter approach was
used, with collation of data from medical records of HIV-
infected children, aged 1 to 12 years, attending three out-
patient clinics in India from 2004 to 2006. The sites
included a tertiary care centre (St. John's Medical College
Hospital, Bangalore), an urban community clinic (Free-
dom Foundation, Bangalore), and a rural community
clinic (Namakkal Government Hospital, Tamil Nadu).
Ethical approval from the local Institutional Review Board
from the study sites was obtained prior to examination of
patient records. Relevant clinical information recorded
included the children's weight, height, detailed history
and physical examination, baseline laboratory values
such as haemoglobin, total white blood cell count and
CD4+ T cell count. Specific information on use of iron
supplements as recorded in the medical chart was noted.
The place of residence was taken from the address given to
the clinic while registering for medical treatment. Out of a
possible 387 children from all sites, 248 children with all
clinical points documented simultaneously were included
in the final analysis, while 139 with missing height, hae-
moglobin, or clinical staging documentation were
excluded. Children were diagnosed and classified accord-
ing to clinical and immunological categories according to
WHO criteria [7]. Ambulatory management of children
attending these clinics included routine clinical monitor-
ing, treatment of minor infections, cotrimoxazole proph-
ylaxis, Anti-Retroviral Therapy (ART) administration and
nutritional supplementation.
Anemia was defined as a haemoglobin concentration of <
11 g/dL, and severe anemia defined as haemoglobin of <
7 g/dL, based on the WHO description of anemia [8].
Information about the children's weight and height was
retrieved from the medical records. Z scores were calcu-
lated for each child using EpiInfo Nutstat (version 3.4.3,
Centers for Disease Control and Prevention, Atlanta Geor-
gia) and used to express the standard deviation in SD
units from the age- and gender-based reference growth
standards developed by the National Center for Health
Statistics [9,10]. Weight-for-age Z score less than -2 SD,
height-for-age Z score less than -2 SD and weight-for-
height Z score less than -2 SD were considered consistent
with underweight, stunting and wasting respectively.
Mean and standard deviations were used to describe nor-
mally distributed data from the subjects' demographic,
anthropometric and laboratory measurements. Categori-
cal and continuous data were compared using chi-square
and Kruskal-Wallis tests respectively. The Spearman rank
correlation test was used to determine the relationship
between different continuous variables. A p value of <
0.05 was considered significant. Odds ratios and 95%
confidence intervals were estimated using univariate
logistic regression analyses to evaluate the association of
nutrition status, HIV clinical stage, CD4+ count, and ART
with anemia. Variables with univariate p-values < 0.2 were
included in a multivariate logistic regression model and
retained if their p-value was < 0.05. Statistical analyses
were performed using SAS software version 9.1 (SAS Insti-
tute Inc., Cary, NC, US).
Results
Study population
Among 248 children who were included, 57% were
males, and mean age was 7 years (SD: 3.4 yrs) (Table 1).
The majority of the children had no or mild symptoms of
HIV infection (69% in WHO Clinical Stage 1 and 2).
Advanced disease was present in 31% of children (WHO
Clinical Stage 3 and 4). Thirty-four percent had no evi-
dence of immunosuppression, 44% had mild-to-
advanced immunosuppression and 22% of children were
severely immunosuppressed based on the age-stratified
CD4 thresholds adopted by the WHO classification[7].BMC Pediatrics 2009, 9:37 http://www.biomedcentral.com/1471-2431/9/37
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ART naïve children constituted 77% of the total popula-
tion, and the remaining 23% of the children had been on
ART for an average period of 1.2 years. When compared to
children included in the final analysis, excluded children
with missing data (n = 139) had no significant differences
in hemoglobin values, place of residence (urban versus
rural), age and clinical stage.
Anemia in the study population
The overall prevalence of anemia was 66%, and 8% had
severe anemia (Hb < 7 g/dL). The mean haemoglobin was
9.95 g/dL (SD: 1.93). As shown in Figure 1, haemoglobin
levels were lower in the pre-school age group, compared
to the 7–12 year age group. The prevalence of anemia in
clinical stages 1, 2, 3 and 4 was 51%, 58%, 87% and 72%
respectively. Haemoglobin level was significantly lower
among those with advanced and severe clinical stages,
compared to those in stage 1 and 2 (9.2 gm/dl vs. 10.3
gm/dl; p = 0.03). With respect to immunological stage,
anemia was present in 85% of those with advanced or
severe immunosuppression while only 56% of children
with mild or no immunosuppression were anemic (p <
0.01).
Risk factors and correlates for anemia
In univariate logistic regression analyses, age younger
than 6 years (Table 2; Odds Ratio [OR]: 2.68; 95% Confi-
dence Intervals [CI]: 1.55, 4.61), advanced HIV disease
stage, (OR: 3.47; 95% CI: 1.83, 6.57) and severe immun-
odeficiency (OR: 4.5; 95% CI: 2.01, 10.0) were signifi-
cantly correlated with higher odds of anemia. A rural
address was more likely to be associated with the presence
of anemia; among 119 children who hailed from a rural
setting 83% had anemia, whereas 43% of the 129 children
from an urban background had anemia (p < 0.01). On the
other hand, use of ART was associated with a 70% reduced
odds of having anemia (p < 0.01). A total of 50 children
were receiving institutionalized care at the time of data
recording, and anemia was found to be less prevalent in
this group compared to those children living at home with
their families (44% vs. 67%, respectively, p < 0.01). Ane-
mia was also associated with pulmonary tuberculosis;
hemoglobin in those children with and without tubercu-
losis was 8.9 and 10.2 g/dl respectively (p < 0.01). There
was no significant association between prevalence of ane-
mia with gender, use of cotrimoxazole prophylaxis, or
type of antiretroviral drug (zidovudine versus stavudine).
Table 1: Characteristics of 248 HIV-infected children
Characteristic Mean (SDb)/Proportion
Age, years 7.24 years (3.44)
Gender (boys) 56.45%
HIV Staging
Stage 1 and 2 68.95%
Stage 3 and 4 31.05%
Severe immunodeficiencya 21.77%
CD4 count 582 cells/mm3 (401)
Weight-for-age Z score (WAZ) -1.98 (1.45)
Height-for-age Z score (HAZ) -1.71 (1.89)
Underweight (WAZ < -2) 55.24%
Stunting (HAZ < -2) 46.37%
Wasting (weight-for-height Z score < -2) 34.27%
On antiretroviral therapy (ART) 22.58%
Hemoglobin 9.95 g/dl (1.93)
HIV/TB co-infection 21.77%
a Immunodeficiency defined according to age-stratified WHO classification [7]; CD4 count < 750 for 1–3 year old children; < 350 for 3–5 year olds; 
and < 200 for older than 5 years.
bSD: Standard deviationBMC Pediatrics 2009, 9:37 http://www.biomedcentral.com/1471-2431/9/37
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In multivariate analyses, children of pre-school age were
three times more likely to be anemic compared to chil-
dren of school age (Table 2; OR: 2.87; 95% CI: 1.45, 5.70;
p < 0.01). The odds of having anemia in HIV-infected chil-
dren from rural areas were 12 times higher compared to
children from urban areas (OR: 12.04; 95% CI: 5.64,
26.00; p < 0.01). Children with WHO stage 3 or 4 HIV dis-
ease were 7 times more likely to have anemia compared to
children with WHO stage 1 or 2 HIV disease (OR: 6.95;
95% CI: 3.06, 15.79; p < 0.01). HIV-infected children with
stunting had over 3 times the odds of having anemia com-
pared to children without stunting (OR: 3.24; 95% CI:
1.65, 6.35; p < 0.01). Supplementation with iron or mul-
tivitamins was associated with 56% reduced odds of ane-
mia (OR: 0.44; 95% CI: 0.22, 0.90; p = 0.03). In a separate
model, where iron or multivitamin supplements and cor-
related variables such as advanced HIV disease stage and
severe immunodeficiency were not included, coinfection
with pulmonary tuberculosis was also associated with
higher odds of anemia (OR: 3.36; 95% CI: 1.43, 7.89; p <
0.01).
Prevalence of growth failure
The proportion of underweight and stunted children in
the population was 55% and 46% respectively (Table 1).
Only 34% of children were wasted (weight-for-height Z
score < -2) indicating that proportional growth failure is
more likely in the setting of HIV infection rather than
acute weight loss over a short period. Being underweight
(weight-for-age Z score < -2) was associated with
advanced HIV disease stage (p = 0.019) while stunting (p
= 0.06) and wasting (p = 0.5) did not correlate with clini-
cal stage, suggesting that cachexia and disproportionate
weight loss are the more typical pattern of advanced dis-
ease progression in HIV-infected children. Children on at
least 6 months of ART were less likely to be underweight
compared to those who were ART-naïve (38% versus
60%; p = 0.002).
Prevalence of anemia by nutritional status
Anemia was significantly associated with poor growth
(WAZ, HAZ < -2) and advanced HIV disease status (p <
0.005). To examine anemia prevalence by different cate-
gories of malnutrition, children were stratified into those
with mild or moderate (Z scores -3 to -2) versus severe (Z
Distribution of hemoglobin levels among children of different age groups, pre-school (1–6 yrs) and school-going (7–12 yrs) Figure 1
Distribution of hemoglobin levels among children of different age groups, pre-school (1–6 yrs) and school-
going (7–12 yrs).
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scores < -3) degrees of being underweight, stunted or
wasted. The reference population for this analysis was the
group of children with no malnutrition (Figure 2). The
prevalence ratios (PR) of anemia among the various cate-
gories were as follows: mild-to-moderate underweight sta-
tus: 1.29 (95% CI: 1.01, 1.65); severe underweight status:
1.63 (95% CI: 1.31, 2.04); mild-to-moderate stunting:
1.52 (95% CI: 1.22, 1.89); severe stunting: 1.52 (95% CI:
1.21, 1.9); mild-to-moderate wasting: 1.17 (95% CI: 0.94,
1.46) and severe wasting: 1.19 (95% CI: 0.91, 1.55).
Notably, there was a lack of association between anemia
prevalence and wasting.
Discussion
As with previous studies from resource-limited settings
[11-17], our data suggest that there is a high prevalence of
anemia and growth failure among children living with
HIV infection in India. Both anemia and growth failure
were associated with advanced HIV disease among chil-
dren in this report. In a meticulously conducted review on
the global prevalence of HIV-associated anemia, Calis et al
Table 2: Correlates of Anemia in HIV-infected children (n = 248)
Risk Factors Univariate correlates Multivariate correlatesa
Odds ratio (95% CI) p-value Odds ratio (95%CI) p-value
Socio-demographic
Age (Pre-school vs. school-age)b 2.68 (1.55, 4.61) < 0.01 2.87 (1.45, 5.70) < 0.01
Sex (males vs. females) 0.97 (0.58, 1.62) 0.89
Rural vs. urban 6.45 (3.57, 11.68) < 0.01 12.09 (5.64, 25.96) < 0.01
HIV and care-related
Advanced HIV stage (Stage 3,4 vs. 1,2) 3.47 (1.83, 6.57) < 0.01 6.95 (3.06, 15.79) < 0.01
Advanced/severe immunodeficiencyc 4.48 (2.01, 10.0) < 0.01
Antiretroviral therapy (ART) 0.29 (0.16, 0.53) < 0.01
ART type (d4T vs. AZT) 1.35 (0.43, 4.30) 0.81
Use of cotrimoxazole 1.15 (0.68, 1.92) 0.61
TB/HIV co-infection 3.29 (1.57, 6.92) < 0.01 3.36 (1.43, 7.89) < 0.01d
Use of nutritional supplements (multivitamins, iron) 0.68 (0.40, 1.16) 0.15 0.44 (0.22, 0.90) 0.03
Care (institutionalized vs. home-based) 0.38 (0.20, 0.72) < 0.01
Anthropometric
Underweight 2.56 (1.51, 4.34) < 0.01
Stunting 3.21 (1.85, 5.56) < 0.01 3.24 (1.65, 6.35) < 0.01
Wasting 1.58 (0.91, 2.76) 0.11BMC Pediatrics 2009, 9:37 http://www.biomedcentral.com/1471-2431/9/37
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reported that anemia was a common complication occur-
ring in 50–90% of children living with HIV in both
resource-limited and resource-rich settings and that ane-
mia prevalence was over three times higher among these
children when compared with those without HIV infec-
tion[6]. Recent longitudinal studies show that anemia is
an independent predictor of mortality among children
with HIV infection[18].
Children in the pre-school age group are at considerably
higher risk for developing anemia, possibly due to their
increased growth requirements and higher frequency of
gastrointestinal infections. The vulnerability of this age
group and heightened propensity for developing anemia
has been consistently reported in other studies [19]. This
point has particular relevance in practice and policy impli-
cations as interventions targeted toward younger age
groups are likely to have maximum benefits. The
increased vulnerability of HIV-infected children hailing
from a rural setting for developing anemia was high-
lighted in our report. Increased anemia prevalence among
rural children has been demonstrated within the general
population, as in the recent National Family Health Sur-
vey-3 results within India [20], and is often attributed to
diminished quality of nutritional intake. National reports
also indicate that the rural population has higher HIV
prevalence than the urban population [21]. Taken
together, nutritional interventions aimed at improving
quality of life among HIV-infected children should
include strategies relevant in rural settings in India.
Not surprisingly, our data indicate that anemia was more
severe among those with advanced disease stage and a
higher degree of immunosuppression. Both adult [2-4]
and paediatric studies [11,12,15,22,23] have demon-
strated a higher anemia prevalence among those with
more advanced disease. A haemoglobin value of < 8 gm/
dL that is unresponsive to non-ART treatment has been
included as a criterion for WHO Stage 3 clinical classifica-
tion, and is considered as adequate criterion for initiating
antiretroviral therapy [24]. Advanced HIV disease may be
associated with deficiencies of other micronutrients in
children; such as vitamin A which is thought to have a role
in erythropoiesis and iron transport [25] The presence of
opportunistic infection among those with advanced dis-
ease can further compound anemia. The finding that HIV-
infected children with pulmonary tuberculosis were three
times more likely to have anemia is consistent with other
reports that indicate that co-infection with tuberculosis is
a potent risk factor for anemia, particularly severe anemia
[26]. Another potential contributing factor is anemia of
chronic inflammation where there is hepcidin-mediated
decreased intestinal iron absorption and increased conser-
vation of iron within the reticuloendothelial system
resulting in decreased erythropoiesis [27].
Prevalence Ratio (PR) for anemia by categories of malnutrition (underweight, stunting, wasting) Figure 2
Prevalence Ratio (PR) for anemia by categories of malnutrition (underweight, stunting, wasting). Anemia is sig-
nificantly associated with the underweight state and with stunting, but not with wasting. WAZ: weight for age Z score; HAZ: 
height for age Z score; WAHZ: weight-for-height Z score.
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The myriad etiologies of anemia among children with
HIV have been well summarized previously [6]. Common
causes include nutrient deficiencies, HIV-mediated sup-
pression of erythropoiesis, drug effects, other opportunis-
tic infections and HIV-associated malignancies. In
resource-limited settings, nutritional deficiencies abound,
especially iron, folic acid, zinc and vitamin A deficien-
cies[28]. Iron deficiency is particularly interesting in this
population; although frequently reported in HIV-infected
subjects, studies with an HIV-uninfected control group
did not clearly suggest increased prevalence of iron defi-
ciency among HIV-infected children in comparison to
uninfected children [11,29]. Observational studies have
raised concerns that iron supplementation may have
adverse consequences in HIV infection [30-33]. Further
studies are needed in order to unravel the questions on
iron and HIV infection.
There is limited data analysing the effect of pre-existing
anemia on disease progression among children with HIV
infection who are also at high risk for nutritional deficien-
cies [34]. In multivariate analysis, our data indicated that
receipt of nutritional supplements was significantly and
independently associated with decreased odds of being
anemic. A randomized controlled study from Tanzania
reported that women who took multivitamin supplemen-
tation during pregnancy and postpartum period showed
improved hematologic status; a beneficial effect was also
seen among their children who were less likely to have
microcytic hypochromic anemia [35]. The improved
hematologic status among children may have contributed
to a better clinical outcome. It is conceivable that treat-
ment of anemia and provision of nutritional supplements
in HIV-infected children will have a beneficial effect inde-
pendent of antiretroviral therapy in improving morbidity
and mortality, although this has not been unequivocally
demonstrated among children living in resource limited
settings[36,37].
In general, poor growth is reported in as many as 50% of
HIV-infected children [16]. The prevalence of malnutri-
tion among HIV-infected children reported from Indian
studies has a wide range (17% to 62%) owing to differing
definitions [38-40]. Growth failure may be a direct conse-
quence of the HIV infection, secondary to the clinical ill-
ness associated with HIV, a function of the child's adverse
environment, or a combination of these factors. It is prob-
able that, independent of HIV infection, malnutrition can
reduce immunological function and can impair that
child's ability to resolve acute infections. Low weight for
age, like low haemoglobin, was an independent predictor
of mortality among HIV-infected children in Zam-
bia[16,34]. The pattern of growth failure among the chil-
dren in this study suggested the prevalence of both
relatively acute (underweight or low weight-for-age) and
chronic growth failure (stunted or low height-for-age).
The overall prevalence of wasting (low weight-for-height)
was low, as seen in our study, suggesting that the majority
of children with growth failure as indicated by under-
weight or stunting, were nevertheless, normally propor-
tioned. Importantly, our data also indicated that HIV-
infected children who were underweight and stunted were
also more likely to be anemic. In particular, multivariate
analyses indicated that stunting was independently asso-
ciated with increased prevalence of anemia in this cohort.
The beneficial effect of ART on anemia and growth param-
eters has been demonstrated previously [41,42]. A large
longitudinal analysis from South India that included a
cohort of 295 children (mean age, 7.6 years; median base-
line CD4 percentage, 14%) who were newly initiated on
ART reported that baseline prevalence of anemia (Hb < 11
gm/dL) was 66% and that of severe malnutrition (weight-
for-age Z score < -2) was 35% [43]. Within just 6 months
of ART initiation, a significant increase in haemoglobin
and weight gain (1.6 gm/dL and 2 kg, respectively) was
noted [43]. As the analyses reported here represent cross-
sectional data, a clear improvement was not demon-
strated in this cohort. However, the finding that provision
of nutritional supplements is independently associated
with better health parameters needs to be explored fur-
ther.
The retrospective design of the study precluded the use of
concomitant HIV-negative controls. In comparison with
non-infected children, HIV-infected children are likely to
have increased nutritional requirements, poor appetite
and reduced intake due to illness and socioeconomic fac-
tors [16]. Anemia is also likely to be more prevalent
among HIV-infected children compared to the general
population and may be attributed to its multifactorial
nature. Nutritional deficiencies may be magnified in this
setting, opportunistic infections and parasitic infestations
may result in increased losses, and the presence of chronic
infection may depress erythropoeisis [6]. The WHO rec-
ommends a 10% increase in energy intake for asympto-
matic HIV-infected children, with further increases of 20–
30% and 50–100% for those children who are sympto-
matic and experiencing weight loss respectively[44]. There
are no specific recommendations with respect to iron sup-
plementation in HIV-infected children. Observational
studies may show benefit of iron and other nutritional
supplements for HIV-infected populations; however no
clear evidence is present to base recommendations of iron
supplementation in HIV-infected children [45].
The retrospective nature of the study limited our under-
standing of the extent to which ART and nutritional inter-
ventions can improve overall nutritional status among
children. Children with missing data were not included in
the analyses, hence the prevalence and correlationsBMC Pediatrics 2009, 9:37 http://www.biomedcentral.com/1471-2431/9/37
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reported in this study reflect only a proportion of all the
HIV-infected children in this region. Study limitations
also included the non-standardization of haemoglobin
estimation methods used across sites; two of the sites used
an automated haematology analyzer while the third site
used the manual Sahli's method. Additionally, the specific
etiology of anemia and growth failure has not been
addressed in this study. Despite these limitations, this
study yields important epidemiological information on
anemia and growth failure among children with HIV
infection in India, and highlights the need for further
large scale prospective studies to understand the scale and
etiology of the problem so as to plan appropriate inter-
ventions.
Conclusion
Our study reinforces the finding that anemia, growth fail-
ure, and malnutrition are major manifestations of HIV
infection in Indian children with prognostic significance.
Identification of major independent risk factors for ane-
mia such as age younger than 6 years, rural residence and
co-infection with pulmonary tuberculosis can guide
appropriate therapeutic interventions. Our data high-
lights the beneficial effect of antiretroviral therapy and
iron/multivitamin supplementation in reducing risk of
anemia. In addition to continuing efforts to improving
access to antiretroviral therapy, it is time to pay attention
to further refining our therapeutic strategies by making
nutritional counselling, nutrition supplementation and
sustainable nutritional interventions an integral part of
our overall approach to helping children with HIV live as
normal a life as possible.
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